account_balance
Investment manager · 13F filer · SEC CIK 1958125
Catalio Capital Management, LP
Reported value$532Mas of Jun 30, 2026
Positions39 11 new, 13 sold out
Top 10 weight56.7%AVLN alone is 10%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
AVLNAvalyn Pharmaceuticals Inc
10.4%New
JNJJohnson & Johnson
6.6%New
GILDGilead Sciences Inc
6.4%Added +64%
BBIOBridgebio Pharma Inc
6.4%Added +5%
SNDXSyndax Pharmaceuticals Inc
5.0%Added +16%
DFTXDefinium Therapeutics Inc
5.0%Trimmed −46%
BMYBristol-myers Squibb Co
4.5%
PBLSParabilis Medicines Inc
4.2%New
NTRANatera Inc
4.2%Added +16%
INCYIncyte Corp
4.1%Added +5%
SEPNSepterna Inc
3.4%Added +82%
MLYSMineralys Therapeutics Inc
3.3%Added +48%
AVLNAvalyn Pharmaceuticals Inc
10.4%New
JNJJohnson & Johnson
6.6%New
GILDGilead Sciences Inc
6.4%Added +64%
BBIOBridgebio Pharma Inc
6.4%Added +5%
SNDXSyndax Pharmaceuticals Inc
5.0%Added +16%
DFTX5.0%BMY4.5%PBLS4.2%NTRA4.2%INCY4.1%SEPN3.4%MLYS3.3%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
AVLN Avalyn Pharmaceuticals Inc 10.4% NewJNJ Johnson & Johnson 6.6% NewGILD Gilead Sciences Inc 6.4% Added +64%BBIO Bridgebio Pharma Inc 6.4% Added +5%SNDX Syndax Pharmaceuticals Inc 5.0% Added +16%DFTX Definium Therapeutics Inc 5.0% Trimmed −46%BMY Bristol-myers Squibb Co 4.5% HeldPBLS Parabilis Medicines Inc 4.2% NewNTRA Natera Inc 4.2% Added +16%INCY Incyte Corp 4.1% Added +5%SEPN Septerna Inc 3.4% Added +82%MLYS Mineralys Therapeutics Inc 3.3% Added +48%
What changed